Target: Pediatrics, Immunology, Stem cell
Scientific Responsible: Prof. Franco Locatelli
Italian CME Credit
Allogeneic hematopoietic stem cell transplantation (HSCT) is a
curative treatment for pediatric patients with many hematological diseases.
The indications for HSCT in children are well
defined for acute leukemia, as well as for patients with non-malignant disease.
HSCT from HLA-identical sibling or unrelated
donors, such as new techniques of graft manipulation using
haploidentical donor graft, provides a high chance of cure for
those patients. The field of HSCT is rapidly evolving with the
possibility to perform targeted immunotherapy with CAR-T
cells for acute lymphoblastic leukemia, B-cell lymphomas and
solid tumors. More recently, the first results of gene therapy for
hereditary diseases, open new perspectives of treatment for
patients with thalassemia, sickle cell disease, primary
immune-deficiencies and metabolic disorders.
The meeting will address all the relevant aspects of indication and results of HSCT in pediatric population, focusing on new insights on gene therapy for hereditary diseases, as well as on the newest results obtained through approaches of immunotherapy. Ethical and regulatory aspects related to these new therapies will be discussed, as well. Recognized, outstanding international leaders will deliver the main lectures, but also high-level research talks selected from the best abstracts submitted by attendees will be presented.